Save

Galacto-oligosaccharides ameliorate dysbiotic Bifidobacteriaceae decline in Japanese patients with type 2 diabetes

于Beneficial Microbes
著者:
M. Gonai Department of Diabetes and Endocrinology, Kantoh Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, Kanagawa 236-0004, Japan.

Search for other papers by M. Gonai in
Current site
Google Scholar
PubMed
Close
,
A. Shigehisa Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan.

Search for other papers by A. Shigehisa in
Current site
Google Scholar
PubMed
Close
,
I. Kigawa Department of Diabetes and Endocrinology, Kantoh Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan.

Search for other papers by I. Kigawa in
Current site
Google Scholar
PubMed
Close
,
K. Kurasaki Department of Diabetes and Endocrinology, Kantoh Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan.

Search for other papers by K. Kurasaki in
Current site
Google Scholar
PubMed
Close
,
O. Chonan Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan.

Search for other papers by O. Chonan in
Current site
Google Scholar
PubMed
Close
,
T. Matsuki Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan.

Search for other papers by T. Matsuki in
Current site
Google Scholar
PubMed
Close
,
Y. Yoshida Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan.

Search for other papers by Y. Yoshida in
Current site
Google Scholar
PubMed
Close
,
M. Aida Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi, Tokyo 186-8650, Japan.

Search for other papers by M. Aida in
Current site
Google Scholar
PubMed
Close
,
K. Hamano Department of Diabetes and Endocrinology, Kantoh Rosai Hospital, 1-1 Kizukisumiyoshi, Nakahara, Kawasaki, Kanagawa 211-8510, Japan.

Search for other papers by K. Hamano in
Current site
Google Scholar
PubMed
Close
, and
Y. Terauchi Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, Kanagawa 236-0004, Japan.

Search for other papers by Y. Terauchi in
Current site
Google Scholar
PubMed
Close

Gut microbiota affects the host’s metabolism, and it is suggested that there are differences in gut microbiota composition between patients with type 2 diabetes and healthy individuals. Additionally, dysbiosis may increase the concentration of lipopolysaccharides (LPS), causing metabolic endotoxemia, which induces impaired glucose tolerance. Several studies have reported relationships between metabolic diseases and the gut microbiota; and prebiotics, such as oligosaccharides, are commonly consumed to regulate gut microbiotas in healthy individuals. Galacto-oligosaccharides (GOS) are a major prebiotic, which specifically increase Bifidobacteriaceae abundance. Recent studies have reported that Bifidobacteriaceae improved metabolic endotoxemia or impaired glucose tolerance. However, there are few studies reporting the effects of GOS on patients with type 2 diabetes. In the current study, we compared clinical parameters, faecal gut microbiota, their associated metabolic products and their components such as LPS, and LPS-binding protein (LBP) produced by the host, between patients with diabetes and healthy controls. We then assessed the effects of GOS on glycaemic control, and gut microbiotas and metabolites in patients with type 2 diabetes in a double-blind controlled manner. LBP levels were significantly higher in patients with diabetes than those of healthy subjects, which was consistent with previous reports. The abundance of Bifidobacteriaceae and the diversity of intestinal microbiota were significantly lower in patients with diabetes than in healthy subjects. Interestingly, Bifidobacteriaceae was markedly restored in patients with diabetes after consumption of GOS, whereas LBP and glucose tolerance did not improve during this short-term trial period. In the present study, we demonstrated that GOS can ameliorate dysbiosis in patients with diabetes, and continuous intake of GOS may be a promising method for managing type 2 diabetes.

内容统计数据

全部期间 过去一年 过去30天
摘要浏览次数 0 0 0
全文浏览次数 767 358 49
PDF下载次数 789 340 28